Characterization of Selective Covalent inhibitors of USP7- AACR Poster
Abstract- The ubiquitin-specific protease 7 (USP7) has emerged as an attractive antitumor target due to its critical roles in several cancer signaling pathways as well as its essential role in maintaining Foxp3+ T-regulatory cell (Treg) functions. Pharmacological inhibition of USP7 is therefore expected to have both direct anti-tumor activity and activity in promoting anti-tumor immunity. […]
Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs
Abstract- There are several challenges towards the development and clinical use of small molecule inhibitors, which are currently the main type of targeted therapies towards intracellular proteins. PROteolysis-TArgeting Chimeras (PROTACs) exploit the intracellular ubiquitin-proteasome systemto selectively degrade target proteins. Recently, small-molecule PROTACs with high potency have been frequently reported. In this review, we summarize the […]
Immune Regulation by Protein Ubiquitination: Roles of the E3 Ligases VHL and Itch
[et_pb_section admin_label=”section”] [et_pb_row admin_label=”row”] [et_pb_column type=”4_4″][et_pb_text admin_label=”Text”]Abstract – Protein ubiquitination is an important means of post-translational modification which plays an essential role in the regulation of various aspects of leukocyte development and function. The specificity of ubiquitin tagging to a protein substrate is determined by E3 ubiquitin ligases via defined E3-substrate interactions.In this review, we […]
Protein Misfolding-Neurodegeneration
[et_pb_section bb_built=”1″][et_pb_row][et_pb_column type=”4_4″][et_pb_text] Abstract- Mammalian cells remove misfolded proteins using various proteolytic systems, including the ubiquitin (Ub)-proteasome system (UPS), chaperone mediated autophagy (CMA) and macroautophagy. The majority of misfolded proteins are degraded by the UPS, in which Ub-conjugated substrates are deubiquitinated, unfolded and cleaved into small peptides when passing through the narrow chamber of the […]
Ubiquitination and Cancer
Abstract- Dynamic modulation and post-translational modification of proteins are tightly controlled biological processes that occur in response to physiological cues. One such dynamic modulation is ubiquitination, which marks proteins for degradation via the proteasome, altering their localization, affecting their activity, and promoting or interfering with protein interactions. Hence, ubiquitination is crucial for a plethora of […]
Hanson Wade’s Targeted Protein Degradation Conference
“Encapsulating the excitement of the field of protein degradation, the 2nd TPD Summit 2019 is the definitive comprehensive and industry-dedicated summit for the field of protein degradation – focused on optimizing target validation, improving medicinal chemistry & rational design, and ultimately accelerating the translation of selective, bioavailable and effective protein degraders into clinical trials.” Progenra […]
Cambridge Healthtech Institute’s Annual Discovery on Target Conference
CHI’s conference on PROTACs and Targeted Protein Degradation will bring together a diverse group of chemists and biologists to discuss the prospects as well as the challenges underlying strategies for targeted protein degradation. This will be preceded by a conference that discusses emerging ubiquitin and autophagy targets for therapeutic intervention. Progenra CEO Dr. Butt will […]
International BIO Convention in Philadelphia
More than 18,000 attendees from companies in 67 countries will meet to “celebrate the global importance of innovation in biotech.” Progenra looks forward to meeting with collaborators and future partners and learning about the latest technological innovations and ideas in drug discovery. This is the largest gathering of Biotech professionals in the world, and we are lucky enough to […]
Neurodegenerative Drug Discovery Europe Conference
Paris, France. ” Multiple clinical failures in the neurodegenerative field have sparked realization that there is a critical need for discussion and debate between neurodegenerative drug developers to drive clinical success. NDD Europe will overcome the translational challenges facing neurodegenerative drug developers by exploring the future biomarkers of neurodegeneration, improving preclinical modelling to increase clinical predictability […]